New EMA strategy to include old people in drug evaluation
Drug development and evaluation processes will take greater account of older patients, according to the European Medicines Agency’s geriatric medicines strategy (PDF, 86K).
The strategy acknowledges the growing needs of the ageing population, and sets out the EMA’s four-year vision to tackle the gaps in knowledge of drug safety and efficacy in older people.
Plans include setting up an advisory group comprising a range of healthcare practitioners with expertise in geriatric care.
Citation: The Pharmaceutical Journal URI: 11069671
Recommended from Pharmaceutical Press